{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:07:57Z","timestamp":1789708077388,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Deciphera Pharmaceuticals, LLC","id":[{"id":"https:\/\/ror.org\/038hbfs18","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"DOI":"10.1007\/s40271-026-00840-3","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:34:17Z","timestamp":1789706057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3566-1004","authenticated-orcid":false,"given":"Heather L.","family":"Gelhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn N.","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Zeringo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsion","family":"Fikre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Harrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"840_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102491","volume":"112","author":"S Stacchiotti","year":"2023","unstructured":"Stacchiotti S, Durr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102491.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"840_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn HL, Tong S, McQuarrie K, et al. Patient-reported symptoms of tenosynovial giant cell tumors. Clin Ther. 2016;38(4):778\u201393. https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.008.","journal-title":"Clin Ther"},{"issue":"18","key":"840_CR3","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1080\/14796694.2025.2520744","volume":"21","author":"M Van de Sande","year":"2025","unstructured":"Van de Sande M, Blay JY, Tap W, et al. The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review. Future Oncol. 2025;21(18):2385\u2013400. https:\/\/doi.org\/10.1080\/14796694.2025.2520744.","journal-title":"Future Oncol"},{"issue":"2","key":"840_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/jmrs.421","volume":"68","author":"H Nguyen","year":"2021","unstructured":"Nguyen H, Butow P, Dhillon H, Sundaresan P. A review of the barriers to using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine cancer care. J Med Radiat Sci. 2021;68(2):186\u201395. https:\/\/doi.org\/10.1002\/jmrs.421.","journal-title":"J Med Radiat Sci"},{"issue":"1","key":"840_CR5","doi-asserted-by":"publisher","DOI":"10.2196\/ijmr.9325","volume":"7","author":"MJ Mastboom","year":"2018","unstructured":"Mastboom MJ, Planje R, van de Sande MA. The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life. Interact J Med Res. 2018;7(1):e4. https:\/\/doi.org\/10.2196\/ijmr.9325.","journal-title":"Interact J Med Res"},{"key":"840_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisako.2025.100907","volume":"13","author":"FS Fahmy","year":"2025","unstructured":"Fahmy FS, ElAttar M, Farhan AH, Sadek SI, Mahmoud MA, Mahmoud HF. Satisfactory functional outcomes and low recurrence rates at a mean 10-year follow-up after combined staged synovectomy and external radiotherapy for diffuse pigmented villonodular synovitis of the knee. J ISAKOS. 2025;13:100907. https:\/\/doi.org\/10.1016\/j.jisako.2025.100907.","journal-title":"J ISAKOS."},{"issue":"11","key":"840_CR7","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","volume":"76","author":"EC Keystone","year":"2017","unstructured":"Keystone EC, Taylor PC, Tanaka Y, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017;76(11):1853\u201361. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211259.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"840_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","volume":"27","author":"CD Coon","year":"2018","unstructured":"Coon CD, Cook KF. Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores. Qual Life Res. 2018;27(1):33\u201340. https:\/\/doi.org\/10.1007\/s11136-017-1616-3.","journal-title":"Qual Life Res"},{"issue":"1","key":"840_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11136-024-03798-7","volume":"34","author":"A Trigg","year":"2025","unstructured":"Trigg A, Ayasse ND, Coon CD. Conceptualizing meaningful between-group difference in change over time: a demonstration of possible viewpoints. Qual Life Res. 2025;34(1):151\u201360. https:\/\/doi.org\/10.1007\/s11136-024-03798-7.","journal-title":"Qual Life Res"},{"issue":"6","key":"840_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/ar2890","volume":"11","author":"B Bruce","year":"2009","unstructured":"Bruce B, Fries JF, Ambrosini D, et al. Better assessment of physical function: item improvement is neglected but essential. Arthritis Res Ther. 2009;11(6):R191. https:\/\/doi.org\/10.1186\/ar2890.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"840_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jclinepi.2006.06.025","volume":"61","author":"M Rose","year":"2008","unstructured":"Rose M, Bjorner JB, Becker J, Fries JF, Ware JE. Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol. 2008;61(1):17\u201333. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.06.025.","journal-title":"J Clin Epidemiol"},{"issue":"10445","key":"840_CR12","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","volume":"403","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom H, Bhadri V, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10445):2709\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(24)00885-7.","journal-title":"Lancet"},{"key":"840_CR13","unstructured":"ClinicalTrials.gov. Study of vimseltinib for tenosynovial giant cell tumor (MOTION) (NCT05059262). 2024. https:\/\/clinicaltrials.gov\/study\/NCT05059262. Accessed 24 Aug 2026."},{"issue":"1","key":"840_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0099-0","volume":"3","author":"HL Gelhorn","year":"2019","unstructured":"Gelhorn HL, Ye X, Speck RM, et al. The measurement of physical functioning among patients with tenosynovial giant cell tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS). J Patient Rep Outcomes. 2019;3(1):6. https:\/\/doi.org\/10.1186\/s41687-019-0099-0.","journal-title":"J Patient Rep Outcomes"},{"issue":"10197","key":"840_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(19)30764-0.","journal-title":"Lancet"},{"issue":"4","key":"840_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17453674.2021.1922161","volume":"92","author":"M Van De Sande","year":"2021","unstructured":"Van De Sande M, Tap WD, Gelhorn HL, et al. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. Acta Orthop. 2021;92(4):493\u20139. https:\/\/doi.org\/10.1080\/17453674.2021.1922161.","journal-title":"Acta Orthop"},{"key":"840_CR17","volume-title":"Item response theory for psychologists","author":"SE Embretson","year":"2000","unstructured":"Embretson SE, Reise SP. Item response theory for psychologists. Mahwah, New Jersey (NJ), USA: Lawrence Erlbaum Associates Publishers; 2000."},{"issue":"1","key":"840_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00217-6","volume":"4","author":"RM Speck","year":"2020","unstructured":"Speck RM, Ye X, Bernthal NM, Gelhorn HL. Psychometric properties of a custom Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function short form and worst stiffness numeric rating scale in tenosynovial giant cell tumors. J Patient Rep Outcomes. 2020;4(1):61. https:\/\/doi.org\/10.1186\/s41687-020-00217-6.","journal-title":"J Patient Rep Outcomes"},{"issue":"3","key":"840_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-026-04162-7","volume":"35","author":"HL Gelhorn","year":"2026","unstructured":"Gelhorn HL, Cutts KN, Harrow B, et al. Mixed-methods to define meaningful change using exit interview and clinical trial data in patients with tenosynovial giant cell tumor (TGCT). Qual Life Res. 2026;35(3):57.","journal-title":"Qual Life Res"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00840-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00840-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00840-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:34:27Z","timestamp":1789706067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00840-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":19,"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00840-3","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Deciphera Pharmaceuticals, LLC sponsored this research study, participating in the design of the study and writing of the manuscript.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Heather L. Gelhorn, Katelyn N. Cutts, Tsion Fikre, and Yipin Han work for Evidera, a scientific research consultancy.\u00a0Evidera was paid to conduct this work by\u00a0Deciphera\u00a0Pharmaceuticals, LLC.\u00a0Brooke Harrow, Christopher Tait, Amanda Saunders, and Nicholas A.\u00a0Zeringo\u00a0are employees of\u00a0Deciphera\u00a0Pharmaceuticals, LLC.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Qualified scientific and medical researchers can address requests for de-identified individual participant data that underlie the results reported in this article to info@deciphera.com. Proposals for data will be evaluated and approved by\u00a0Deciphera\u00a0Pharmaceuticals, LLC at its sole discretion. All approved researchers must sign a data access agreement before accessing the data. Data will be available as soon as possible but no later than within 1 year of the acceptance of the article for publication and for 3 years after article publication.\u00a0Deciphera\u00a0Pharmaceuticals, LLC will not share data from\u00a0identified\u00a0participants or a data\u00a0dictionary.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conception and design:\u00a0HLG, KNC, CT, AS, BH. Acquisition of data:\u00a0HLG, KNC, TF, YH. Analysis and interpretation of data:\u00a0HLG, KNC, TF, YH, CT, AS, BH. Drafting the article:\u00a0HLG. Revising it for intellectual content:\u00a0KNC; YH; TF; CT; NZ; AS; BH. Final approval of the completed article:\u00a0HLG, KNC, TF, YH, CT, NZ, AS, BH.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}